Mauna Kea Technologies Secures an Equity Financing Facility to Support Its Development

PARIS & CAMBRIDGE, Mass.--()--Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announces the implementation of an equity financing facility with Kepler Cheuvreux.

The CEO of the Company, acting with a delegation from the Board and in accordance with the 12th resolution approved by the General Meeting of Shareholders on May 4, 2016, decided today to implement this equity financing facility.

Under the terms of this facility, and subject to certain conditions, Kepler Cheuvreux has committed itself to subscribing 1,850,000 new shares (representing an estimated €5.6 million(1) of capital increase) over the course of the next twenty four months, at its own pace and timing.

Kepler Cheuvreux being a financial intermediary and a guarantor of the transaction, the shares will be issued based on the volume-weighted average price of the trading days preceding the issue, with a discount of 6.5%.

If the financing facility were to be used in full(2), a shareholder with 1.00% of the capital today would see that holding drop to 0.91% of capital on a non-diluted basis(3), and to 0.82% of capital on a diluted basis(4). Mauna Kea Technologies has the ability to stop this equity financing at any time.

The number of share issued and listed under this facility shall be published in Euronext Paris market notices, and on the website of Mauna Kea Technologies.

The present issuance does not require the production of a prospectus subject to AMF approval.

(1) Based on the indicative volume-weighted average price of the last twenty trading days of Mauna Kea Technologies shares.
(2) Leading to the issuance of a maximum of 1,850,000 new shares
(3) Based on the 19,156,838 shares comprising the share capital of Mauna Kea Technologies as of September 30, 2016
(4) Under the assumption of the issuance of all 2,259,539 shares arising from the exercise of all existing dilutive instruments as of the date of the present press release (including this equity line), it being specified that to date 27% of these instruments are « out of the money ».

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Contacts

Mauna Kea Technologies
Benoit Jacheet
CFO
investors@maunakeatech.com
or
United States
Zack Kubow / Lee Roth
The Ruth Group
646-536-7020 / 7012
zkubow@theruthgroup.com / lroth@theruthgroup.com
or
U.S. Media
The Ruth Group
Christopher Hippolyte, 646-536-7023
chippolyte@theruthgroup.com
or
France and Europe
NewCap - Investor Relations
Florent Alba, +33 (0)1 44 71 94 94
maunakea@newcap.fr

Contacts

Mauna Kea Technologies
Benoit Jacheet
CFO
investors@maunakeatech.com
or
United States
Zack Kubow / Lee Roth
The Ruth Group
646-536-7020 / 7012
zkubow@theruthgroup.com / lroth@theruthgroup.com
or
U.S. Media
The Ruth Group
Christopher Hippolyte, 646-536-7023
chippolyte@theruthgroup.com
or
France and Europe
NewCap - Investor Relations
Florent Alba, +33 (0)1 44 71 94 94
maunakea@newcap.fr